 3. At least 4 weeks from the completion of any previous cytotoxic chemotherapy, 6 weeks from biological therapy monoclonal antibodies or cancer immunotherapy immune checkpoint modulators or 2 weeks from targeted therapy receptor tyrosine kinase inhibitors at time of administration of AMC303. 